Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210Phase 3Recruiting
- Lead sponsor
- Intra-Cellular Therapies, Inc. (Industry)
- Enrollment
- 300 (estimated)
- Start date
- 25 Jan 2024
- Primary completion
- 28 Apr 2032 (estimated)
- Study completion
- 28 Apr 2032
- Last update posted
- 25 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Lumateperone Drug
Conditions and primary outcome
- Schizophrenia
- Bipolar Disorder
- Autism Spectrum Disorder
Primary outcome
Incidence of Common Adverse Events (Up to 6 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06229210.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06229210 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.